Redox Reprogramming of the Tumor Microenvironment: Targeting Extracellular ROS to Restore Antitumor Immunity
Bioconjugate Chemistry · 2026
DOI: 10.1021/acs.bioconjchem.6c00362 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Zichuang Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang050018, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Reactive Oxygen Species, Neoplasms. Die Arbeit nennt 256 Literaturangaben. Gefördert von: S&T Program of Shijiazhuang.
Abstract (Originalsprache)
Reactive oxygen species (ROS) are central regulators of redox homeostasis yet exert paradoxical effects in cancer. While ROS overproduction can directly kill tumor cells, persistent oxidative stress in the tumor microenvironment (TME) paradoxically impairs antitumor immunity. Excess extracellular ROS oxidize critical thiols on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, disrupting immune synapse formation and effector function. ROS also compromise dendritic cells (DCs) antigen presentation via endoplasmic reticulum (ER) stress and lipid accumulation, and attenuate immunogenic cell death (ICD) by oxidizing damage-associated molecular patterns such as high mobility group box 1 protein (HMGB1) from its immunostimulatory disulfide form to an inert sulfonated state. These disruptions create a major barrier to effective immunotherapy. This review highlights that redox imbalance, rather than ROS abundance, determines therapeutic outcomes. We discuss mechanisms of ROS-mediated immune suppression, emphasizing oxidative modification of immune cell thiols, DC dysfunction, and disruption of danger signaling. Recent ROS-scavenging strategies, including small-molecule antioxidants and nanomedicine platforms, enable spatially and temporally controlled modulation of oxidative stress to restore immune competence. Emerging evidence supports strategies integrating transient ROS generation for tumor killing with sustained clearance to preserve immune signaling. We further outline challenges and future directions, including redox threshold identification, feedback-responsive systems, and biomarker-guided patient stratification. Precision redox modulation thus emerges as a promising approach to overcome immune suppression and enhance cancer immunotherapy durability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang050018, China.
- State Key Laboratory of Metastable Materials Science and Technology, Nano-biotechnology Key Lab of Hebei Province, Yanshan University, Qinhuangdao066004, China.
- TPD Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang050035, China.
ORCID-Profile: Zichuang Xu
Förderung
- S&T Program of Shijiazhuang
Zitieren
APA
Xu, Z., Wang, L., Zhang, J., He, Y., & Wang, J. (2026). Redox Reprogramming of the Tumor Microenvironment: Targeting Extracellular ROS to Restore Antitumor Immunity. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.6c00362
Vancouver
Xu Z, Wang L, Zhang J, He Y, Wang J. Redox Reprogramming of the Tumor Microenvironment: Targeting Extracellular ROS to Restore Antitumor Immunity. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.6c00362
BibTeX
@article{Xu2026,
author = {Xu, Zichuang and Wang, Li and Zhang, Jinhui and He, Yaqian and Wang, Jinxu},
title = {Redox Reprogramming of the Tumor Microenvironment: Targeting Extracellular ROS to Restore Antitumor Immunity},
journal = {Bioconjugate Chemistry},
year = {2026},
doi = {10.1021/acs.bioconjchem.6c00362}
}
EUVIMED